Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA CAR-T for Relapsed or Refractory Multiple Myeloma
NCT04626752Phase 1Unknown
- Sponsor
- Senlang Bio
- Start
- Apr 2020
- Primary completion
- Mar 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BCMA-CAR-T in multiple myeloma (MM), sponsored by Senlang Bio. Primary endpoints: Number of Participants with Severe/Adverse Events as a Measure of Safety at 28 days and CAR-T Cell expansion level at 24 months. Status: unknown.
02
Drugs
BCMA-CAR-T
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04626752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04626752.